AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26125277
Drug: Sertraline (n=60)
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sertraline (n=60)
Trial: 23102845
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg FSH im once a day for 4 days (N = 5)
Trial: 23102845
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg FSH sc on Day 3 and Day 5 (N = 4)
Trial: 23102845
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg FSH plus 2.5 mg LH sc on Day 3 and Day 5 (N = 4)
Trial: 16501860
Drug: Low-dose gemcitabine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose gemcitabine infusion (250 mg/m2)
Trial: 16501860
Drug: Standard-dose gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose gemcitabine infusion (1000 mg/m2)
Trial: 12928902
Drug: Acyclovir 200
RxNorm normalized name: acyclovir 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir 200 mg five times/day for 3 weeks (Group A)
Trial: 12928902
Drug: Acyclovir 200
RxNorm normalized name: acyclovir 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir 200 mg five times/day for 1 year (Group B)
Trial: 12928902
Drug: Acyclovir 200
RxNorm normalized name: acyclovir 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir 200 mg five times/day in combination with MMF 1 g twice daily for 1 year (Group C)
Trial: 11164664
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) 0.1 mg/kg injected subcutaneously three times a week
Trial: 11164664
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline solution injected at the same times as GH
Trial: 9217519
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of lorazepam and haloperidol
Trial: 2823840
Drug: 1500 aPTT‐U
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 aPTT‐U low molecular weight heparin plus 0.5 mg dihydroergotamine (HNMD; Embolex NM)
Trial: 2823840
Drug: 5000 IU
RxNorm normalized name: D 5000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5000 IU of the heparin‐dihydroergotamine combination Heparin‐Dihydergot (twice daily)
Trial: 49984
Drug: Chemotherapy (Hydroxyurea)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (Hydroxyurea) only
Trial: 30983166
Drug: Atorvastatin 40mg
RxNorm normalized name: AMLODIPINE 5MG/ATORVASTATIN 40MG TAB
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40mg daily
Trial: 28902426
Drug: Surgical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical therapy aiming at pocket elimination with systemic antibiotics
Trial: 28902426
Drug: Surgical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical therapy aiming at pocket elimination with antiseptic agent for implant surface decontamination
Trial: 28902426
Drug: Surgical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical therapy aiming at pocket elimination with both systemic antibiotics and antiseptic agent
Trial: 28902426
Drug: Surgical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical therapy aiming at pocket elimination (control group)
Trial: 21366634
Drug: H. pylori
RxNorm normalized name: H. PYLORI AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. pylori eradication therapy (ranitidine bismuth citrate 400 mg and clarithromycin 500 mg twice daily for 2 weeks)
Trial: 12970274
Drug: GH at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH at 25.0 microg/kg x day (pediatric dose)
Trial: 12970274
Drug: GH at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH at 12.5 microg/kg x day (adult dose)
Trial: 12970274
Drug: No GH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No GH treatment (control)
Trial: 10784079
Drug: Full-day treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-day treatment classroom only
Trial: 10784079
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of parent training with classroom treatment
Trial: 8678501
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of azasetron (2.5 mg bolus followed by 7.5 mg continuous infusion for 24 hrs)
Trial: 8678501
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of azasetron
Trial: 8678501
Drug: Bolus intravenous
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus intravenous injection of azasetron (10 mg)
Trial: 2059393
Drug: Enalapril 20
RxNorm normalized name: enalapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 20 mg/day for 8 weeks
Trial: 2059393
Drug: Nitrendipine 20
RxNorm normalized name: nitrendipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine 20 to 40 mg/day for 8 weeks (after enalapril)
Trial: 28335701
Drug: Whole-body vibration
RxNorm normalized name: Insects (whole body), mite dermatophagoides farinae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-body vibration therapy (VG)
Trial: 28335701
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapy (CG)
Trial: 26043560
Drug: Tiaogan Lipi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiaogan Lipi Recipe (TLR), one dose per day for 12 weeks
Trial: 26043560
Drug: Placebo, one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, one dose per day for 12 weeks
Trial: 21593661
Drug: Raltegravir (RAL)
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Raltegravir (RAL) 400 mg twice daily
Trial: 15261317
Drug: nitroglycerin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nitroglycerin + ephedrine 0.1 mg/kg i.v.
Trial: 15261317
Drug: nitroglycerin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nitroglycerin + ephedrine 0.15 mg/kg i.v.
Trial: 15261317
Drug: trimethaphan +
RxNorm normalized name: trimethaphan
DrugBank: Trimethaphan (DB01116)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trimethaphan + ephedrine 0.1 mg/kg i.v.
Trial: 15261317
Drug: trimethaphan +
RxNorm normalized name: trimethaphan
DrugBank: Trimethaphan (DB01116)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trimethaphan + ephedrine 0.15 mg/kg i.v.
Trial: 1583417
Drug: Methylphenidate (optimal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (optimal dose for 6 weeks)
Trial: 1583417
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 week without medication)
Trial: 1583417
Drug: Methylphenidate (return
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (return to medication after placebo)
Trial: 3159547
Drug: Depo-medroxyprogesterone acetate
RxNorm normalized name: medroxyprogesterone Injection [Depo-Provera]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depo-medroxyprogesterone acetate (DMPA) 50 mg/month
Trial: 3159547
Drug: Depo-medroxyprogesterone acetate
RxNorm normalized name: medroxyprogesterone Injection [Depo-Provera]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depo-medroxyprogesterone acetate (DMPA) 100 mg/month
Trial: 3159547
Drug: Depo-medroxyprogesterone acetate
RxNorm normalized name: medroxyprogesterone Injection [Depo-Provera]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depo-medroxyprogesterone acetate (DMPA) 200 mg/month
Trial: 3159547
Drug: Testosterone cypionate
RxNorm normalized name: Testosterone Cypionate
DrugBank: Testosterone cypionate (DB13943)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone cypionate (TC) 250 mg/month
Trial: 3159547
Drug: Post-discontinuation of
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-discontinuation of DMPA
Trial: 3159547
Drug: DMPA administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DMPA administration
Trial: 29043412
Drug: Etirinotecan pegol
RxNorm normalized name: Etirinotecan pegol
DrugBank: Etirinotecan pegol (DB14951)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etirinotecan pegol (EP) 145 mg/m2 Q21d
Trial: 29043412
Drug: Irinotecan 350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan 350 mg/m2 Q21d
Trial: 25391324
Drug: Bridge exercises
RxNorm normalized name: benzalkonium chloride Topical Cream [Abridge Cold Sore]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bridge exercises with a sling and micro vibrations (therapy group)
Trial: 21563962
Drug: 1250 mg
RxNorm normalized name: bran 1250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1250 mg of Neuravena®
Trial: 21563962
Drug: 2500 mg
RxNorm normalized name: inulin 2500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2500 mg of Neuravena®
Trial: 18486257
Drug: Increased basal/total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased basal/total daily insulin ratio (B/TD ratio) from about 0.35 to about 0.46+/‐0.12 without change of total insulin daily dose
Trial: 12937241
Drug: Pre-emptive oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-emptive oral ganciclovir therapy
Trial: 12937241
Drug: Conventional deferred
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional deferred treatment (control group)
Trial: 9250252
Drug: Inhaled furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled furosemide 20 mg
Trial: 3735283
Drug: Subacromial injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subacromial injection of 40 mg of triamcinalone acetonide
Trial: 3735283
Drug: Oral indomethacin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral indomethacin, 100 mg/day
Trial: 23529570
Drug: Dapagliflozin (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin (up to 10 mg/day)
Trial: 23529570
Drug: Glipizide (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glipizide (up to 20 mg/day)
Trial: 10965198
Drug: Preoperative CA125
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative CA125 levels <35 IU/ml
Trial: 10965198
Drug: Preoperative CA125
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative CA125 levels >=35 IU/ml
Trial: 744492
Drug: Pomeroy's Kroener's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomeroy's Kroener's or a combination of both surgical procedures
Trial: 24284086
Drug: Oral 5-aminolevulinic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 5-aminolevulinic acid (5-ALA)
Trial: 21176727
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of roflumilast (ROF) 500 µg
Trial: 21176727
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of roflumilast (ROF) 150 µg
Trial: 18637718
Drug: 10% citric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% citric acid solution
Trial: 18637718
Drug: 5.25% sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.25% sodium hypochlorite (NaOCl) solution
Trial: 9295593
Drug: Neoral (converted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoral (converted from Sandimmune on a 1:1 dosing basis)
Trial: 30167655
Drug: Modified Mindfulness-Based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Mindfulness-Based Stress Reduction (MBSR) training, weekly 2-hour classes and 20 minutes of daily home practice over 8 weeks.
Trial: 22147287
Drug: Domperidone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone (10 mg three times a day for 10 days)
Trial: 22147287
Drug: Metoclopramide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (10 mg three times a day for 10 days)
Trial: 22147287
Drug: Metoclopramide (follow-on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (follow-on prescription)
Trial: 20653798
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination therapy (polypill) with aspirin 81 mg, enalapril 2.5 mg, atorvastatin 20 mg, and hydrochlorothiazide 12.5 mg
Trial: 18411606
Drug: Local adrenaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local adrenaline administration into the surgical field before wound closure
Trial: 8605133
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine oestrogen vaginal cream
Trial: 1524045
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate (MA) 240 mg/day orally for at least 2 months
Trial: 6388425
Drug: Naftidrofuryl (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naftidrofuryl (600 mg daily)
Trial: 29052225
Drug: Peripheral nerve
RxNorm normalized name: Peripheral nerve antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral nerve blocks with pre‐emptive ibuprofen and paracetamol
Trial: 20179751
Drug: Standard 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard 6 month anti-tuberculosis (TB) therapy
Trial: 11790638
Drug: Transdermal xanomeline,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal xanomeline, an M1‐selective cholinergic agonist, administered for 4 months.
Trial: 11790638
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered for 4 months.
Trial: 10618939
Drug: Rectal paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal paracetamol 1.3 g
Trial: 17416906
Drug: Diclofenac 50
RxNorm normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 50 mg
Trial: 10618939
Drug: Rectal paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal paracetamol and diclofenac
Trial: 8543846
Drug: hMG preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hMG preparation containing a 3:1 ratio of FSH/LH (Group A)
Trial: 1935730
Drug: Oxamniquine 750
RxNorm normalized name: oxamniquine
DrugBank: Oxamniquine (DB01096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxamniquine 750 mg
Trial: 1935730
Drug: Oxamniquine 1000
RxNorm normalized name: oxamniquine
DrugBank: Oxamniquine (DB01096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxamniquine 1000 mg
Trial: 1935730
Drug: Oxamniquine 1250
RxNorm normalized name: oxamniquine
DrugBank: Oxamniquine (DB01096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxamniquine 1250 mg
Trial: 6775094
Drug: medroxyprogesterone acetate,
RxNorm normalized name: medroxyprogesterone acetate, micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: medroxyprogesterone acetate, 20 mg
Trial: 30422368
Drug: Esomeprazole 10
RxNorm normalized name: esomeprazole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 10 mg once daily
Trial: 30422368
Drug: Esomeprazole (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole (10 mg or 20 mg)
Trial: 17507833
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated equine estrogens (CEE) 0.625 mg/d
Trial: 17507833
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (TD E2) 0.05 mg/d
Trial: 28938478
Drug: Glucose-insulin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-insulin infusion
Trial: 20419730
Drug: Individual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual treatment at a mental health clinic
Trial: 18701831
Drug: Fluoxetine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine treatment (20‐40 mg/day)
Trial: 18701831
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (STPP and fluoxetine)
Trial: 17085376
Drug: HRT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT with 1 mg/day micronized 17beta-estradiol and 10 mg/day dydrogesterone for 14 days of each 28-day cycle
Trial: 1325762
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg of conjugated estrogen with 2.5 mg of micronized medroxyprogesterone acetate daily continuously (group C-2.5)
Trial: 1325762
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg of conjugated estrogen and 5.0 mg of micronized medroxyprogesterone acetate daily continuously (group C-5)
Trial: 1325762
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg of conjugated estrogen on days 1 through 25 and 5 mg of micronized medroxyprogesterone acetate on days 14 through 25 (group S-5)
Trial: 6363096
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg once daily metoprolol Durules
Trial: 6363096
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg metoprolol and 25 mg hydrochlorothiazide (Selokomb)
Trial: 6363096
Drug: Change from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Change from double dose of metoprolol Durules to combination therapy
Trial: 30885955
Drug: Dapagliflozin 10
RxNorm normalized name: dapagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 10 mg daily for 8 weeks
Trial: 30025009
Drug: Subcrestal implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcrestal implants (1 mm subcrestally placed)
Trial: 30025009
Drug: Crestal implants
RxNorm normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crestal implants (placed at the bone crest level)
Trial: 26655606
Drug: Dexamethasone intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone intravitreal implant 0.7 mg
Trial: 21519291
Drug: ACU-4429 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACU-4429 (2 mg to 75 mg)
Trial: 17439908
Drug: Interferon‐beta1a (IFN‐beta1a),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon‐beta1a (IFN‐beta1a), 22 mug subcutaneously weekly
Trial: 11904789
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard pharmacological antiemetic treatment: metoclopramide and dexamethasone i.v.)
Trial: 29524454
Drug: Vamorolone (0.1-20.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vamorolone (0.1-20.0 mg/kg single doses; 1.0-20 mg/kg/day for 14 days)
Trial: 25786050
Drug: Multicomponent exercise
RxNorm normalized name: meningococcus B, multicomponent vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multicomponent exercise programme (24 twice-weekly sessions of combined aerobic, muscle strength training exercises and education)
Trial: 23924790
Drug: Ipilimumab 10
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab 10 mg/kg + GVAX
Trial: 19149323
Drug: Cognitive-rehabilitation and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-rehabilitation and problem-solving therapy intervention
Trial: 1245792
Drug: Chenodeoxycholic acid
RxNorm normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chenodeoxycholic acid (CDC), 750 mg per day
Trial: 1245792
Drug: Phenobarbital (PB),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbital (PB), 90 or 180 mg
Trial: 1245792
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CDC and PB
Trial: 30796143
Drug: 12-week regimen
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week regimen of doxycycline or clarithromycin/hydroxychloroquine after a 2-week open-label regimen of intravenous ceftriaxone
Trial: 30796143
Drug: 2-week regimen
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2-week regimen of intravenous ceftriaxone
Trial: 28698186
Drug: Fasting serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting serum insulin levels
Trial: 28698186
Drug: Fourth quartile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fourth quartile of insulin